Clinical Trials Sponsored by Cotton Incorporated

Total 4162 results

Bausch & Lomb Incorporated

Completed

Clinical Study to Evaluate the Safety and Performance of the enVista® One-Piece Hydrophobic Acrylic Trifocal Intraocular Lens in Subjects Undergoing Cataract Extraction

Cataract

Canada
Bausch & Lomb Incorporated

Completed

Biotrue ONEday Contact Lenses With EPG03 Packaging Solution Compared to Biotrue ONEday Contact Lenses

Contact Lens Wearer

United States
Bausch & Lomb Incorporated

Completed

A Study to Evaluate the Safety and Effectiveness of a Contact Lens Cleaning and Disinfecting Solution

Refractive Ametropia

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-548

Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Mild or Moderate Hepatic Impairment

Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty

Acute Pain

United States
Torax Medical Incorporated

Completed

A Post-Approval Study of the LINX® Reflux Management System

Gastroesophageal Reflux Disease (GERD)

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

Cystic Fibrosis

United States, Spain, United Kingdom, New Zealand, Israel, Australia, Ireland, Germany, Sweden, Czechia, Portugal, Hungary
Bausch & Lomb Incorporated

Completed

Evaluate the Safety and Effectiveness of the enVista® One-Piece Hydrophobic Acrylic Trifocal Intraocular Lens

Cataract

United States
Sound Pharmaceuticals, Incorporated

Active, not recruiting

SPI-1005 for the Treatment of Meniere's Disease (STOPMD-3)

Meniere Disease | Ménière

United States
Bausch & Lomb Incorporated

Completed

"Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness"

Ocular Redness

United States
Bausch & Lomb Incorporated

Completed

Kalifilcon A Toric Compared to Commercially Available Lenses

Refractive Ametropia

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 1 Dose Escalation Study of VX-993 in Healthy Participants

Pain

United Kingdom
Sound Pharmaceuticals, Incorporated

Enrolling by invitation

SPI-1005 Treatment in Severe COVID-19 Patients

Coronavirus Infection | Covid19 | Corona Virus Infection | Coronavirus

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF)

Cystic Fibrosis

Belgium, Spain, Australia, Canada
Vertex Pharmaceuticals Incorporated

Completed

Long-term Safety of Lumacaftor/Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation

Cystic Fibrosis

United States, Canada
Sound Pharmaceuticals, Incorporated

Completed

SPI-1005 for the Treatment of Patients With Meniere's Disease

Meniere's Disease

United States
Bausch & Lomb Incorporated

Completed

Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis

Allergic Conjunctivitis

United States
Bausch & Lomb Incorporated

Completed

Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis

Seasonal Allergic Conjunctivitis

United States
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years

Cystic Fibrosis

United States, United Kingdom, Canada, Australia, Germany
OncoSec Medical Incorporated

Terminated

Phase II Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma (CTCL)

Mycosis Fungoides (MF) | Cutaneous T Cell Lymphomas (CTCL)

United States
OncoSec Medical Incorporated

Completed

Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC (TNBC)

ER-Negative PR-Negative HER2-Negative Breast Cancer

United States
OncoSec Medical Incorporated

Completed

Trial of pIL-12 Electroporation Malignant Melanoma (IL-12MEL)

Melanoma

United States
OncoSec Medical Incorporated

Terminated

Trial of pIL-12 Electroporation in Squamous Cell Carcinoma of the Head and Neck (IL12HNSCC)

Head and Neck Squamous Cell Carcinoma

United States
Vertex Pharmaceuticals Incorporated

Completed

Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 1 Dose Escalation Study of VX-708 in Healthy Participants

Pain

United States
Bausch & Lomb Incorporated

Completed

Evaluation of Visual Acuity of the Envista One-piece Acrylic Toric IOL MX60ET

Astigmatism

United States
Vertex Pharmaceuticals Incorporated

Completed

Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del

Cystic Fibrosis

United States, Canada
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Tablet of VX-121/Tezacaftor/Deutivacaftor

Cystic Fibrosis

United States
Bausch & Lomb Incorporated

Completed

A Study to Evaluate the Safety and Effectiveness of a Silicone Hydrogel Custom Contact Lens When Compared to Alden Optical HP Sphere Lens

Contact Lens Wear

United States
Vertex Pharmaceuticals Incorporated

Completed

A Microneurography (MNG) Study of VX-150 in Healthy Participants

Pain

United Kingdom
Bausch & Lomb Incorporated

Completed

Safety and Efficacy of a New Transepithelial Photorefractive Keratectomy Treatment

Ametropia

Philippines
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes

Cystic Fibrosis

Canada, France, Germany, United Kingdom, Israel, Australia, Spain, Netherlands, Denmark, Switzerland
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype

Alpha1-Antitrypsin Deficiency

United States, Germany, Canada, Ireland, Sweden, United Kingdom
Castle Biosciences Incorporated

Completed

5 Year Registry Study to Track Clinical Application of DecisionDx-UM Assay Results and Associated Patient Outcomes (CLEAR)

Uveal Melanoma
Campbell University, Incorporated

Completed

Effects of Physical Therapy on Isometric Neck Retraction Strength and Pain in Patients With Neck Disability

Neck Pain | Strength

United States
Bausch & Lomb Incorporated

Completed

Insertion Clinical Study to Evaluate the Orientation Characteristics of Multiple Kalifilcon A Daily Disposable Toric LD213001 Contact Lenses

Astigmatism

United States
Vertex Pharmaceuticals Incorporated

Terminated

A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy

Cystic Fibrosis

United States, Spain, Ireland, Australia, Israel, United Kingdom, Germany, Canada, Denmark, Poland, Switzerland
Vertex Pharmaceuticals Incorporated

Completed

A Decentralized Study to Evaluate Physical Activity and Cough Frequency Using Wearable Technology in Cystic Fibrosis

Cystic Fibrosis

United States, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis

Cystic Fibrosis

United States, Australia, Belgium, Netherlands
Bausch & Lomb Incorporated

Completed

2-Hour Dispensing Evaluation of Samfilcon A Lenses With EPG01 Packaging Solution Compared to Commercially Available B+L Ultra Lenses

Contact Lens Wearer

United States
Bausch & Lomb Incorporated

Completed

Evaluation of Surface Refractive Index Shift of Kalifilcon A Lenses Compared to Dailies Total 1, Precision 1 and Biotrue ONEday Lenses

Habitual Soft Contact Lens Use

United States
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age

Cystic Fibrosis

United States, Canada, Australia, Ireland, United Kingdom
Bausch & Lomb Incorporated

Completed

Bausch & Lomb Ophthalmic Viscosurgical Device (OVD) Dispersive (DVisc40)

Cataract

United States
Castle Biosciences Incorporated

Terminated

5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results (INTEGRATE)

Cutaneous Melanoma

United States
Bausch & Lomb Incorporated

Completed

Surface Refractive Index Shift and Lens Absorption/Adsorption of Tear Components of Kalifilcon A Lenses vs Dailies Total1 and Precision1

Habitual Soft Contact Lens Use

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)

Cystic Fibrosis

United States, Spain, Ireland, Belgium, Netherlands, United Kingdom, Australia, France, Canada, Denmark, Germany, Italy, Israel
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy

Acute Pain

United States
Torax Medical Incorporated

Completed

An Observational Clinical Feasibility Study of the Magnetic Esophageal Sphincter

Gastroesophageal Reflux Disease

United States, Netherlands, Italy
Bausch & Lomb Incorporated

Completed

Evaluate the Safety and Effectiveness of the Biotrue ONEday for Astigmatism

Astigmatism

United States

3

Subscribe